Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial)

Cancer

Volumn 113, Issue 2, 2008, Pages 396-404

  Van Den Bergh, Karien A M ^a   Essink Bot, Marie Louise ^a   Bunge, Eveline M ^a   Scholten, Ernst Th ^b   Prokop, Mathias ^c   Van Iersel, Carola A ^a   Van Klaveren, Rob J ^a   De Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Kennemer Gasthuis ^*  (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Lung neoplasms; Mass screening; Quality of life; Spiral computed tomography

Indexed keywords

ANXIETY; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; DISTRESS SYNDROME; EARLY DIAGNOSIS; FEMALE; HIGH RISK POPULATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE;

FEMALE; HEALTH; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; QUALITY OF LIFE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 48249128274     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23590     Document Type: Article

References (37)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. Version 2.0. Vol. 2005. Lyon: IARC Press; 2004.
2. American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society; 2007. Available at: http://www.cancer.org/downloads/STT/ CAFF2007PWSecured.pdf. Accessed August 17, 2007.
3. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355:1763-1771.
4. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA. 2007;297:953-961.
5. Gohagan J, Marcus P, Fagerstrom R, Pinsky P, Kramer B, Prorok P. Baseline findings of a randomized feasibility trial of lung cancer screening widi spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest. 2004;126:114-121.
6. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007;120:868-874.
7. Welch HG, Woloshin S, Schwartz LM, et al. Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med. 2007;167:2289-2295.
8. UK National Screening Committee. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. Available at URL: http://www.nsc.nhs.uk/pdfs/criteria.pdf. Accessed June 12, 2007.
9. de Haes JC, de Koning HJ, van Oortmarssen GJ, van Agt HM, de Bruyn AE, van Der Maas PJ. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer. 1991;49:538-544.
10. Essink-Bot ML, Korfage IJ, De Koning HJ. Including the quality-of-life effects in the evaluation of prostate cancer screening: expert opinions revisited? BJU Int. 2003;92(suppl 2):101-105.
11. Xu DM, Gietema H, de Koning H, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer. 2006;54:177-184.
12. Essink-Bot ML, Rijnsburger AJ, van Dooren S, de Koning HJ, Seynaeve C. Women's acceptance of MRI in breast cancer surveillance because of a familial or genetic predisposition. Breast. 2006;15:673-676.
13. Kruijshaar ME, Kerkhof M, Siersema PD, Steyerberg EW, Homs MY, Essink-Bot ML. The burden of upper gastrointestinal endoscopy in patients with Barrett's esophagus. Endoscopy. 2006;38:873-878.
14. Essink-Bot ML, de Koning HJ, Nijs HG, Kirkels WJ, van der Maas PJ, Schroder FH. Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst. 1998;90:925-931.
15. Khanna D, Tsevat J. Health-related quality of life-an introduction. Am J Manag Care. 2007;13(suppl 9):S218-S223.
16. McCaffery KJ, Barratt AL. Assessing psychosocial/quality of life outcomes in screening: how do we do it better? J Epidemiol Community Health. 2004;58:968-970.
17. Essink-Bot ML, Stouthard ME, Bonsel GJ. Generalizability of valuations on health states collected with the EuroQolc-questionnaire. Health Econ. 1993;2:237-246.
18. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in 9 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1171-1178.
19. Kind P, Brooks R, Rabin R. EQ-5D concepts and methods: a development history. Dordrecht, the Netherlands: Springer; 2005.
20. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233.
21. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095-1108.
22. van der Bij AK, de Weerd S, Cikot RJ, Steegers EA, Braspenning JC. Validation of the dutch short form of the state scale of the Spielberger State-Trait Anxiety Inventory: considerations for usage in screening outcomes. Community Genet. 2003;6:84-87.
23. Brom D, Kleber RJ. De Schok Verwerkings Lijst [The Dutch version of the Impact of Event Scale]. Nederlands Tijdschrift voor de Psychologie. 1985;40:164-168.
24. Horowitz M, Wilner N, Alvarez W Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979;41:209-218.
25. Mudde AN, Willemsen MC, Kremers S, De Wies H. Meetinstrumenten voor onderzoek naar roken en stoppen met roken [Measurement Instruments used in Research with Regard to Smoking and Smoking Cessation]. 2nd ed. The Hague: STIVORO; 2006. Available from URL: http://www.stivoro.nl/upload/_publdocs/ meetinstrumenten_3.pdf. Accessed October 8, 2006.
26. Statistic Netherlands. Statline. Available at URL: http://statline.cbs. nl. 2005. Accessed May 8, 2007.
27. Van der Ploeg HM, Defares PB, Spielberger CD. Handleiding bij de Zelf-Beoordelings Vragenlijst ZBV [Manual for the Dutch Adaptation of the STAI-Y]. Lisse, the Netherlands: Swets & Zeitlinger; 1980.
28. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582-592.
29. Cullen J, Schwartz MD, Lawrence WF, Selby JV, Mandelblatt JS. Short-term impact of cancer prevention and screening activities on quality of life. J Clin Oncol. 2004;22:943-952.
30. Rijnsburger AJ, Essink-Bot ML, van Dooren S, et al. Impact of screening for breast cancer in high-risk women on health-related quality of life. Br J Cancer. 2004;91:69-76.
31. Taylor KL, Shelby R, Gelmann E, McGuire C. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. J Natl Cancer Inst. 2004;96:1083-1094.
32. Laaksonen M, Rahkonen O, Martikainen P, Karvonen S, Lahelma E. Smoking and SF-36 health functioning. Prev Med. 2006;42:206-209.
33. Otto SJ, Schroder FH, de Koning HJ. Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias? J Med Screen. 2004;11:89-92.
34. Folkman S. Positive psychological states and coping with severe stress. Soc Sci Med. 1997;45:1207-1221.
35. Brodersen J, Thorsen H, Cockburn J. The adequacy of measurement of short and long-term consequences of false-positive screening mammography. J Med Screen. 2004;11:39-44.
36. Barton MB, Morley DS, Moore S, et al. Decreasing women's anxieties after abnormal mammograms: a controlled trial. J Natl Cancer Inst. 2004;96:529-538.
37. Brodersen J, Thorsen H, Kreiner S. Validation of a condition-specific measure for women having an abnormal screening mammography. Value Health. 2007;10: 294-304.